Cartesian Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:RNAC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities -13.69 M7 M23.11 M17.52 M15.6 M 63.23 M Cash from investing activities 6.2 M354 K1.07 M2.6 M1.29 M 5.32 M Cash from financing activities 124.49 M783 K8.03 M-60 K38 K 8.79 M Free cash flow -19.89 M6.3 M22.03 M14.93 M14.31 M 57.56 M

News

Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?

Johnson & Johnson Touts Positive Results For Lupus Treatment - Johnson & Johnson (NYSE:JNJ)

2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares

H.C. Wainwright abaisse l’objectif de cours de l’action Cartesian Therapeutics à 30€

H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40

Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis (NASDAQ:RNAC)

Les études sur le lupus et le myélome multiple de Cartesian sont mises en pause alors que l'entreprise recentre son développement | Benzinga France

What's Going On With Cartesian Therapeutics Stock Friday? - Cartesian Therapeutics (NASDAQ:RNAC)

BTIG relève son objectif de cours pour Cartesian Therapeutics à 44€

Cartesian Therapeutics stock price target raised to $44 by BTIG

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday - Applied Mat (NASDAQ:AMAT), Gap (NYSE:GAP)

Kyverna Stock: Immune Reset Is Clinically Validated, Market Ignores Potential